Warfarin therapy
231 results
101 - 200
Clopidogrel + ASA for afib: fewer strokes, more hemorrhages (ACTIVE)- Taking vitamin K antagonists after ICH: the good, the bad, and the ugly (CHIRONE)
- Percutaneous left atrial appendage closure reduces AF stroke risk
Prevention of venous thromboembolism - Aortic stenosis
- Treatment approach for atrial fibrillation: rate control or rhythm control?
- Antithrombotic agents in primary health care
- Rivaroxaban + clopidogrel causes somewhat less bleeding than triple therapy in patients with AF undergoing PCI
- Assessment and treatment of a patient with bleeding diathesis
- NOACs preferred over warfarin for nonvalvular atrial fibrillation in patients also taking low-dose aspirin
- Oral anticoagulation for prolonging survival in patients with cancer
- Indications for and implementation of anticoagulant therapy in atrial fibrillation
- Coumadin + aspirin no better than aspirin alone for PAD
- More harm than good with bridge therapy in low-risk VTE patients
- Clinically significant bleeding occurs in 3.8% per year of pts aged 65+ years using warfarin
Vitamin K for improved anticoagulation control in patients receiving warfarin: Cochrane systematic review- ACC/AHA guidelines for atrial fibrillation
- Joint injection okay in anticoagulated patients
- Bleeding risk with warfarin high among elderly, especially older than 80
- Rivaroxaban similar to warfarin for patients with NVAF
- Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation
- Anticoagulation versus placebo for heart failure in sinus rhythm
- Use of antithrombotic medications increases risk of hematuria-related complications
- Heart valve operation: patient follow-up and complications
- Closure of PFO similar to medical therapy for cryptogenic stroke or TIA
- Dual therapy with dabigatran and clopidogrel preferred after PCI for patients with AF (RE-DUAL PCI)
- Dabigatran cost-effective for AF prophylaxis in some patients, not others
- Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
- Transient ischaemic attack (TIA)
- Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack: Cochrane systematic review
- Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy: Cochrane systematic review
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
- Oral anticoagulants for preventing stroke in patients with non‐valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks
- Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack: Cochrane systematic review
- Deep vein thrombosis
- Oral yeast infections
- Anticoagulant therapy in acute (duration less than 48 hours) atrial fibrillation - Image
- Chronic diseases and pregnancy
- Lumbar puncture
- Antiplatelet therapy for patients with non-valvular atrial fibrillation
- Vitamin K antagonists versus antiplatelet therapy after TIA or minor ischaemic stroke of presumed arterial origin
- Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
- Nephrotic syndrome
- Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks: Cochrane systematic review
- Gastroscopy
- Dabigatran associated with increased risk of coronary events
- Bridging anticoagulation in patients with AF associated with more CVEs and bleeding
- Antiplatelet agents and anticoagulants for hypertension
- Systemic lupus erythematosus (SLE)
- Selecting anticoagulant therapy in atrial fibrillation - Image
- Acute coronary syndrome
- Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts
- Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
- Slightly lower risk of major bleeds with apixaban (NNT = 83); no difference in efficacy
- Evaluation of thrombophilia
- Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks: Cochrane systematic review
- VTE recurrence higher in men
- Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
- Oral rivaroxaban as effective as standard therapy for treatment of acute PE
- Anticoagulation therapy versus placebo for pulmonary hypertension
- Anticoagulation reversal with vitamin K doesn't reduce bleeding
- Rivaroxaban effective for acute DVT (EINSTEIN)
- Takotsubo cardiomyopathy
- Management of acute atrial fibrillation
- ACCP 2016: updated guidelines for VTE
- Updated American College of Chest Physicians guideline on antithrombotic therapy for venous thromboembolism
- Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin: Cochrane systematic review
- Chronic heart failure
- Smoking cessation
- Safe use of non-steroidal anti-inflammatory drugs (NSAIDs)
- Acute heart failure and pulmonary oedema
- 2023 American Geriatric Society update on potentially inappropriate medication use in the elderly (Beers List)
- Continuous passive motion for preventing venous thromboembolism after total knee arthroplasty: Cochrane systematic review
- Adverse effects of amiodarone
- Anticoagulants for non-rheumatic atrial fibrillation and a history of stroke or transient ischaemic attacks